

Stephanie M J Fliedner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/246669/publications.pdf>

Version: 2024-02-01

17
papers

827
citations

623574

14
h-index

887953

17
g-index

17
all docs

17
docs citations

17
times ranked

1236
citing authors

#	ARTICLE	IF	CITATIONS
1	Landscape of the mitochondrial Hsp90 metabolome in tumours. <i>Nature Communications</i> , 2013, 4, 2139.	5.8	135
2	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. <i>Clinical Chemistry</i> , 2018, 64, 1646-1656.	1.5	121
3	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1122-1132.	1.8	120
4	Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. <i>Journal of Molecular Medicine</i> , 2015, 93, 93-104.	1.7	118
5	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2017, 177, 103-113.	1.9	82
6	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3295-3307.	1.8	34
7	Genotype and Tumor Locus Determine Expression Profile of Pseudohypoxic Pheochromocytomas and Paragangliomas. <i>Neoplasia</i> , 2013, 15, 435-IN22.	2.3	33
8	Warburg Effect's Manifestation in Aggressive Pheochromocytomas and Paragangliomas: Insights from a Mouse Cell Model Applied to Human Tumor Tissue. <i>PLoS ONE</i> , 2012, 7, e40949.	1.1	32
9	Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. <i>Frontiers in Endocrinology</i> , 2021, 12, 589451.	1.5	25
10	Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas—Effect of Different Statins on Mouse Pheochromocytoma Cells. <i>PLoS ONE</i> , 2014, 9, e97712.	1.1	24
11	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3374-e3383.	1.8	17
12	Hypoxia-Inducible Factor 2 ^{1±} Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. <i>Neoplasia</i> , 2016, 18, 567-576.	2.3	16
13	Ganglioneuromas across age groups: Systematic review of individual patient data. <i>Clinical Endocrinology</i> , 2021, 94, 12-23.	1.2	16
14	Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. <i>Cell and Tissue Research</i> , 2010, 340, 607-612.	1.5	15
15	Pheochromocytoma and paraganglioma: genotype versus anatomic location as determinants of tumor phenotype. <i>Cell and Tissue Research</i> , 2018, 372, 347-365.	1.5	15
16	Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines. <i>PLoS ONE</i> , 2014, 9, e87807.	1.1	14
17	Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. <i>American Journal of Cancer Research</i> , 2015, 5, 1558-70.	1.4	10